Compare Tango Therapeutics Inc. (TNGX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Teucrium Wheat Fund — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Teucrium Wheat Fund trades at $24.38 (market cap $274.59M). The key difference: Tango Therapeutics Inc. is far larger — about 13.7× Teucrium Wheat Fund's market cap, and Teucrium Wheat Fund is more actively traded (203,622 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Teucrium Wheat Fund for 42 Days on average.
| TNGX | WEAT | |
|---|---|---|
Market Cap | $3.75B | $274.59M |
Volume | 9,619,106 | 203,622 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $32.90 | $28.00 |
52-Week Low | $7.50 | $19.88 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
WEAT trades at $24.28, down 0.74% today, with a bearish technical signal from moving averages. Recent news highlights a 25% year-to-date gain as of July 2026, driven by wheat market dynamics, though inflation concerns persist. Key support is at $24, with resistance at $25. The absence of fundamental ratios like P/E and P/S in the data limits valuation clarity, but the ETF's performance is tied to agricultural commodity trends.
The outlook is cautious due to bearish technical indicators and macroeconomic inflation pressures. Opportunities exist if wheat prices rally, but risks include commodity volatility and Federal Reserve policy impacts. Investors should weigh the ETF's lack of traditional company fundamentals against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
